Publication Topic

Sacks NC. 2013. Avoidable costs in U.S. healthcare: The $200 billion opportunity from using medicines more responsibly. IMS Health, June.

Sacks NC, Burgess JF, Cabral HJ, Pizer SD, McDonnell, ME. 2013. Cost sharing and decreased branded oral anti-diabetic medication adherence among elderly Part D Medicare beneficiaries. J Gen Intern Med 28(7):876–885.

Cyr P, Sidhu M, Hussain R, Hromin T, Jensen I, Kuan R. Dual-acting osmotic and stimulant laxative for bowel cleansing in an elderly population: A US payer budget impact analysis. Abstract PCN22, ISPOR 18th Annual International Meeting, 2013.

Jensen I, Ogborne R, Cyr P. A German hospital budget impact model comparing antibiotic therapies in complicated skin and skin structure infections and bacteremia. ISPOR 17th Annual International Meeting, 2012.

Jensen I, Helm T, Cyr P. Impact of complications in solid organ transplants on hospital charges and length of stay. Abstract PSU15, ISPOR 17th Annual International Meeting, 2012.

Wang A, Halbert RJ, Baerwaldt T, Nordyke RJ. 2012. U.S. payer perspectives on evidence for formulary decision-making. J Oncol Pract 8(3 Suppl):22s-27s; doi: 10.1200/JOP.2011.000526. PMID: 22942820.

Jensen I, Helm T, Cyr P. Impact of dysphagia on U.S. hospital charges in patients with comorbid conditions. Abstract PGI9, ISPOR 14th Annual European Congress, 2011.

Jensen I, Helm T, Cyr P. Impact of complications from dysphagia on hospital charges in the United States. Abstract PGI7, ISPOR 14th Annual European Congress, 2011.

Hess G, Nordyke RJ, Hill J, Hulnick S. 2010. Effect of reimbursement changes on erythropoiesis-stimulating agent utilization and transfusions. Am J Hematol 85(11):838-43; doi: 10.1002/ajh.21837. PMID: 20976794.

Olchanski N, Slawsky KA, Plent S, Kado C, Cyr PL. 2010. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a U.S. hospital. Hosp Prac 38(4):138-146; doi: 10.3810/hp.2010.11.351.